<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00235443</url>
  </required_header>
  <id_info>
    <org_study_id>SP0745</org_study_id>
    <nct_id>NCT00235443</nct_id>
  </id_info>
  <brief_title>A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy</brief_title>
  <official_title>A Multi-Center, Open-Label, Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2/3 open-label trial to assess the safety and tolerability of long-term treatment with
      lacosamide (SPM 927) in subjects with painful diabetic neuropathy. The safety and
      tolerability of the different doses of lacosamide will be investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 2/3 open-label trial is being conducted at approximately 100 sites in the US to
      assess the safety and tolerability of long-term treatment with lacosamide (SPM 927) in
      subjects with painful diabetic neuropathy. Approximately 525 subjects will be enrolled. To
      qualify for this trial, subjects with symptoms of painful distal diabetic neuropathy ranging
      in duration from 6 months to 5 years must have completed trials SP665, SP742, or SP768 and,
      in the investigator's opinion, may benefit from long-term administration of lacosamide.
      Subjects will be titrated to their optimal dose of lacosamide (up to 600mg/day). The safety
      and tolerability of the different doses of lacosamide will be investigated throughout the
      trial. In addition, to determine what effect lacosamide has on diabetic neuropathic pain,
      subjects will use a diary to record their daily pain intensity and pain interference with
      sleep and activity. Subjects' quality of life will also be investigated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Adverse Events (AEs) Reported Spontaneously by the Subject or Observed by the Investigator.</measure>
    <time_frame>Throughout the study up to a maximum study period of 2.8 years</time_frame>
    <description>Number of subjects with adverse events (AEs) reported spontaneously by the subject or observed by the investigator (serious and non-serious).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Daily Pain Score Using an 11-point Likert Scale (0-10).</measure>
    <time_frame>Baseline to end of entire treatment phase (maximum study period of 2.8 years).</time_frame>
    <description>Change from Baseline in average daily pain score using an 11-point Likert scale (0-10). On Likert scale, 0=no pain and 10=worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Pain Score as Measured by a 100mm Visual Analogue Scale (VAS).</measure>
    <time_frame>Baseline to end of entire treatment phase (maximum study period of 2.8 years).</time_frame>
    <description>Change from Baseline in average pain score as measured by a 100mm Visual Analogue Scale (VAS). On VAS 0mm=no pain and 100mm=worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Impression of Change (PGIC) From Baseline in Pain.</measure>
    <time_frame>Baseline to Termination Visit</time_frame>
    <description>Patient's Global Impression of Change (PGIC) from Baseline in Pain. Original categorical responses are much worse, moderately worse, mildly worst, no change, mildly better, moderately better, and much better. Reported results are presented as Better (sum of mildly, moderately, or much better), No Change, or Worse (sum of mildly, moderately, or much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Intensity.</measure>
    <time_frame>Baseline to Termination Visit</time_frame>
    <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) for intensity of pain where 0=no pain and 10=most intense pain sensation imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Sharpness</measure>
    <time_frame>Baseline to Termination Visit</time_frame>
    <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) for sharpness of pain where 0=not sharp and 10=most sharp sensation imaginable (&quot;like a knife&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Heat</measure>
    <time_frame>Baseline to Termination Visit</time_frame>
    <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with heat sensation where 0=not hot and 10=the most hot sensation imaginable (&quot;on fire&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Dullness</measure>
    <time_frame>Baseline to Termination Visit</time_frame>
    <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with dullness of pain where 0=not dull and 10=most dull sensation imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Cold</measure>
    <time_frame>Baseline to Termination Visit</time_frame>
    <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with cold sensation where 0=not cold and 10=most cold sensation imaginable (&quot;freezing&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Sensitivity</measure>
    <time_frame>Baseline to Termination Visit</time_frame>
    <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with sensitivity of pain where 0=not sensitive and 10=most sensitive sensation imaginable (&quot;raw skin&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Itchiness</measure>
    <time_frame>Baseline to Termination Visit</time_frame>
    <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with itchiness where 0=not itchy and 10=most itchy sensation imaginable (&quot;like poison oak&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Unpleasantness</measure>
    <time_frame>Baseline to Termination Visit</time_frame>
    <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with unpleasantness where 0=not pleasant and 10=most unpleasant sensation imaginable (&quot;intolerable&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Deep Pain</measure>
    <time_frame>Baseline to Termination Visit</time_frame>
    <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with deep pain where 0=no deep pain and 10=most intense deep pain sensation imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Surface Pain</measure>
    <time_frame>Baseline to Termination Visit</time_frame>
    <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with surface pain where 0=no surface pain and 10=most intense surface pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Pain Interference With Sleep (11-point Likert Scale)</measure>
    <time_frame>Baseline to end of entire treatment phase visit</time_frame>
    <description>Change from Baseline in average pain interference with sleep (11-point Likert scale) where 0=no interference with sleep and 10=worst possible interference with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Pain Interference With Activity (11-point Likert Scale)</measure>
    <time_frame>Baseline to end of entire treatment phase visit</time_frame>
    <description>Change from Baseline in average pain interference with activity (11-point Likert scale) where 0=no interfence with activity and 10=worst possible interference with activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life Using the SF-36 Health Survey - Physical Component Summary (PCS)</measure>
    <time_frame>Baseline to Termination Visit</time_frame>
    <description>Change from Baseline in quality of life using the SF-36 Health Survey - Physical Component Summary (PCS). Values range from 0 to 100 with high values indicating a good condition. Positive change in baseline values indicate improvement in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS)</measure>
    <time_frame>Baseline to Termination Visit</time_frame>
    <description>Change from Baseline in quality of life using the SF-36 Health Survey - Mental Component Summary (MCS). Values range from 0 to 100 with high values indicating a good condition. Positive change in baseline values indicate improvement in quality of life.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">451</enrollment>
  <condition>Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lacosamide</intervention_name>
    <description>Open-label treatment (two times per day) with film-coated tablets include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, and 600mg/day throughout individual study period.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>SPM927</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who completed Study SP665, SP742, or SP768 and, in the investigators opinion,
             might benefit from long-term administration of SPM 927. Exception: subjects who
             prematurely discontinued Study SP742 or SP768 due to lack of efficacy or due to
             intolerability to trial medication may be eligible to participate in Study SP745,
             after consultation with the medical monitor.

        Exclusion Criteria:

          -  Subject has clinically relevant electrocardiogram (ECG) abnormalities, or QT-corrected
             (QTc) interval &gt;=500 milliseconds (ms), and/or a QTc interval increase of &gt;=60ms from
             the mean pre-dose QTc value at Visit 2 of Studies SP665, SP742 or SP768.

          -  Subject has aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt;=3
             times the upper limit of the normal range (ULN) with total bilirubin &gt;=2 times ULN or
             transaminases (AST and/or ALT) &gt;=5 times ULN.

          -  Subject has a clinically relevant medical condition that, in the opinion of the
             investigator, jeopardizes or compromises the subject's ability to participate in this
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>32 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoover</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northport</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stratford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Owings Mills</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>https://www.vimpathcp.com/vimpat-prescribing-information.pdf?v=1491846793</url>
    <description>Product Information</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2005</study_first_submitted>
  <study_first_submitted_qc>October 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2005</study_first_posted>
  <results_first_submitted>August 31, 2009</results_first_submitted>
  <results_first_submitted_qc>August 31, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 5, 2009</results_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Painful Distal Diabetic Neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Trial SP745 (NCT00235443) was conducted in 93 sites in the US and 89 of these sites screened at least 1 subject. The first subject was enrolled on 13Sep2004 and the last subject completed on 25Jul2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lacosamide 100mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="P2">
          <title>Lacosamide 200mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="P3">
          <title>Lacosamide 300mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="P4">
          <title>Lacosamide 400mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="P5">
          <title>Lacosamide 500mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="P6">
          <title>Lacosamide 600mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="85"/>
                <participants group_id="P4" count="205"/>
                <participants group_id="P5" count="39"/>
                <participants group_id="P6" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="108"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="97"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="44"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons for premature termination</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lacosamide 100mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="B2">
          <title>Lacosamide 200mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="B3">
          <title>Lacosamide 300mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="B4">
          <title>Lacosamide 400mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="B5">
          <title>Lacosamide 500mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="B6">
          <title>Lacosamide 600mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="85"/>
            <count group_id="B4" value="205"/>
            <count group_id="B5" value="39"/>
            <count group_id="B6" value="54"/>
            <count group_id="B7" value="451"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="160"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="44"/>
                    <measurement group_id="B7" value="339"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.0" spread="8.16"/>
                    <measurement group_id="B2" value="59.3" spread="10.53"/>
                    <measurement group_id="B3" value="60.5" spread="8.55"/>
                    <measurement group_id="B4" value="57.3" spread="9.43"/>
                    <measurement group_id="B5" value="56.9" spread="9.52"/>
                    <measurement group_id="B6" value="55.5" spread="10.10"/>
                    <measurement group_id="B7" value="58.1" spread="9.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="125"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="205"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="54"/>
                    <measurement group_id="B7" value="451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Adverse Events (AEs) Reported Spontaneously by the Subject or Observed by the Investigator.</title>
        <description>Number of subjects with adverse events (AEs) reported spontaneously by the subject or observed by the investigator (serious and non-serious).</description>
        <time_frame>Throughout the study up to a maximum study period of 2.8 years</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events (AEs) Reported Spontaneously by the Subject or Observed by the Investigator.</title>
          <description>Number of subjects with adverse events (AEs) reported spontaneously by the subject or observed by the investigator (serious and non-serious).</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="205"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="196"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="50"/>
                    <measurement group_id="O7" value="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Daily Pain Score Using an 11-point Likert Scale (0-10).</title>
        <description>Change from Baseline in average daily pain score using an 11-point Likert scale (0-10). On Likert scale, 0=no pain and 10=worst possible pain.</description>
        <time_frame>Baseline to end of entire treatment phase (maximum study period of 2.8 years).</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Daily Pain Score Using an 11-point Likert Scale (0-10).</title>
          <description>Change from Baseline in average daily pain score using an 11-point Likert scale (0-10). On Likert scale, 0=no pain and 10=worst possible pain.</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="204"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="53"/>
                <count group_id="O7" value="442"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.15" spread="2.345"/>
                    <measurement group_id="O2" value="-4.30" spread="1.991"/>
                    <measurement group_id="O3" value="-3.70" spread="2.020"/>
                    <measurement group_id="O4" value="-3.29" spread="1.872"/>
                    <measurement group_id="O5" value="-3.54" spread="1.602"/>
                    <measurement group_id="O6" value="-2.73" spread="2.064"/>
                    <measurement group_id="O7" value="-3.49" spread="1.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Pain Score as Measured by a 100mm Visual Analogue Scale (VAS).</title>
        <description>Change from Baseline in average pain score as measured by a 100mm Visual Analogue Scale (VAS). On VAS 0mm=no pain and 100mm=worst possible pain.</description>
        <time_frame>Baseline to end of entire treatment phase (maximum study period of 2.8 years).</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Pain Score as Measured by a 100mm Visual Analogue Scale (VAS).</title>
          <description>Change from Baseline in average pain score as measured by a 100mm Visual Analogue Scale (VAS). On VAS 0mm=no pain and 100mm=worst possible pain.</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="205"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.83" spread="34.022"/>
                    <measurement group_id="O2" value="-43.06" spread="23.901"/>
                    <measurement group_id="O3" value="-35.24" spread="26.837"/>
                    <measurement group_id="O4" value="-30.06" spread="23.723"/>
                    <measurement group_id="O5" value="-36.73" spread="18.025"/>
                    <measurement group_id="O6" value="-27.70" spread="22.427"/>
                    <measurement group_id="O7" value="-33.39" spread="24.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Global Impression of Change (PGIC) From Baseline in Pain.</title>
        <description>Patients Global Impression of Change (PGIC) from Baseline in Pain. Original categorical responses are much worse, moderately worse, mildly worst, no change, mildly better, moderately better, and much better. Reported results are presented as Better (sum of mildly, moderately, or much better), No Change, or Worse (sum of mildly, moderately, or much worse).</description>
        <time_frame>Baseline to Termination Visit</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Global Impression of Change (PGIC) From Baseline in Pain.</title>
          <description>Patients Global Impression of Change (PGIC) from Baseline in Pain. Original categorical responses are much worse, moderately worse, mildly worst, no change, mildly better, moderately better, and much better. Reported results are presented as Better (sum of mildly, moderately, or much better), No Change, or Worse (sum of mildly, moderately, or much worse).</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="182"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="147"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="34"/>
                    <measurement group_id="O7" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Intensity.</title>
        <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) for intensity of pain where 0=no pain and 10=most intense pain sensation imaginable.</description>
        <time_frame>Baseline to Termination Visit</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Intensity.</title>
          <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) for intensity of pain where 0=no pain and 10=most intense pain sensation imaginable.</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="181"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="2.63"/>
                    <measurement group_id="O2" value="-4.4" spread="3.03"/>
                    <measurement group_id="O3" value="-3.1" spread="2.86"/>
                    <measurement group_id="O4" value="-2.7" spread="2.96"/>
                    <measurement group_id="O5" value="-3.5" spread="2.22"/>
                    <measurement group_id="O6" value="-2.0" spread="2.61"/>
                    <measurement group_id="O7" value="-3.0" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Sharpness</title>
        <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) for sharpness of pain where 0=not sharp and 10=most sharp sensation imaginable (&quot;like a knife&quot;).</description>
        <time_frame>Baseline to Termination Visit</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Sharpness</title>
          <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) for sharpness of pain where 0=not sharp and 10=most sharp sensation imaginable (&quot;like a knife&quot;).</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="181"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="2.76"/>
                    <measurement group_id="O2" value="-4.2" spread="3.07"/>
                    <measurement group_id="O3" value="-3.3" spread="3.25"/>
                    <measurement group_id="O4" value="-2.8" spread="3.20"/>
                    <measurement group_id="O5" value="-3.9" spread="2.51"/>
                    <measurement group_id="O6" value="-1.9" spread="3.00"/>
                    <measurement group_id="O7" value="-3.1" spread="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Heat</title>
        <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with heat sensation where 0=not hot and 10=the most hot sensation imaginable (&quot;on fire&quot;).</description>
        <time_frame>Baseline to Termination Visit</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Heat</title>
          <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with heat sensation where 0=not hot and 10=the most hot sensation imaginable (&quot;on fire&quot;).</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="181"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="3.74"/>
                    <measurement group_id="O2" value="-3.0" spread="3.65"/>
                    <measurement group_id="O3" value="-3.1" spread="3.44"/>
                    <measurement group_id="O4" value="-2.6" spread="3.14"/>
                    <measurement group_id="O5" value="-2.8" spread="2.58"/>
                    <measurement group_id="O6" value="-1.2" spread="2.86"/>
                    <measurement group_id="O7" value="-2.7" spread="3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Dullness</title>
        <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with dullness of pain where 0=not dull and 10=most dull sensation imaginable.</description>
        <time_frame>Baseline to Termination Visit</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Dullness</title>
          <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with dullness of pain where 0=not dull and 10=most dull sensation imaginable.</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="181"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="2.41"/>
                    <measurement group_id="O2" value="-2.6" spread="3.03"/>
                    <measurement group_id="O3" value="-2.6" spread="2.88"/>
                    <measurement group_id="O4" value="-2.4" spread="3.34"/>
                    <measurement group_id="O5" value="-2.4" spread="3.65"/>
                    <measurement group_id="O6" value="-1.8" spread="3.23"/>
                    <measurement group_id="O7" value="-2.4" spread="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Cold</title>
        <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with cold sensation where 0=not cold and 10=most cold sensation imaginable (&quot;freezing&quot;).</description>
        <time_frame>Baseline to Termination Visit</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Cold</title>
          <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with cold sensation where 0=not cold and 10=most cold sensation imaginable (&quot;freezing&quot;).</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="180"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="3.34"/>
                    <measurement group_id="O2" value="-1.9" spread="3.14"/>
                    <measurement group_id="O3" value="-1.2" spread="3.13"/>
                    <measurement group_id="O4" value="-1.7" spread="3.19"/>
                    <measurement group_id="O5" value="-2.2" spread="3.64"/>
                    <measurement group_id="O6" value="-0.5" spread="3.01"/>
                    <measurement group_id="O7" value="-1.5" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Sensitivity</title>
        <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with sensitivity of pain where 0=not sensitive and 10=most sensitive sensation imaginable (&quot;raw skin&quot;).</description>
        <time_frame>Baseline to Termination Visit</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Sensitivity</title>
          <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with sensitivity of pain where 0=not sensitive and 10=most sensitive sensation imaginable (&quot;raw skin&quot;).</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="181"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="4.78"/>
                    <measurement group_id="O2" value="-3.4" spread="3.46"/>
                    <measurement group_id="O3" value="-1.8" spread="3.10"/>
                    <measurement group_id="O4" value="-2.1" spread="3.44"/>
                    <measurement group_id="O5" value="-2.7" spread="3.24"/>
                    <measurement group_id="O6" value="-1.4" spread="3.26"/>
                    <measurement group_id="O7" value="-2.2" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Itchiness</title>
        <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with itchiness where 0=not itchy and 10=most itchy sensation imaginable (&quot;like poison oak&quot;).</description>
        <time_frame>Baseline to Termination Visit</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Itchiness</title>
          <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with itchiness where 0=not itchy and 10=most itchy sensation imaginable (&quot;like poison oak&quot;).</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="181"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="2.94"/>
                    <measurement group_id="O2" value="-2.0" spread="3.19"/>
                    <measurement group_id="O3" value="-1.4" spread="3.26"/>
                    <measurement group_id="O4" value="-1.1" spread="3.03"/>
                    <measurement group_id="O5" value="-2.1" spread="2.57"/>
                    <measurement group_id="O6" value="-0.5" spread="2.79"/>
                    <measurement group_id="O7" value="-1.3" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Unpleasantness</title>
        <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with unpleasantness where 0=not pleasant and 10=most unpleasant sensation imaginable (&quot;intolerable&quot;).</description>
        <time_frame>Baseline to Termination Visit</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Unpleasantness</title>
          <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with unpleasantness where 0=not pleasant and 10=most unpleasant sensation imaginable (&quot;intolerable&quot;).</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="180"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="3.56"/>
                    <measurement group_id="O2" value="-4.0" spread="3.15"/>
                    <measurement group_id="O3" value="-3.3" spread="3.08"/>
                    <measurement group_id="O4" value="-2.9" spread="2.96"/>
                    <measurement group_id="O5" value="-3.3" spread="2.85"/>
                    <measurement group_id="O6" value="-1.5" spread="2.61"/>
                    <measurement group_id="O7" value="-3.0" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Deep Pain</title>
        <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with deep pain where 0=no deep pain and 10=most intense deep pain sensation imaginable.</description>
        <time_frame>Baseline to Termination Visit</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Deep Pain</title>
          <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with deep pain where 0=no deep pain and 10=most intense deep pain sensation imaginable.</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="180"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="3.34"/>
                    <measurement group_id="O2" value="-3.3" spread="3.58"/>
                    <measurement group_id="O3" value="-3.2" spread="3.35"/>
                    <measurement group_id="O4" value="-2.7" spread="3.11"/>
                    <measurement group_id="O5" value="-3.3" spread="2.94"/>
                    <measurement group_id="O6" value="-1.5" spread="2.88"/>
                    <measurement group_id="O7" value="-2.8" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Surface Pain</title>
        <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with surface pain where 0=no surface pain and 10=most intense surface pain imaginable.</description>
        <time_frame>Baseline to Termination Visit</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS)  Surface Pain</title>
          <description>Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with surface pain where 0=no surface pain and 10=most intense surface pain imaginable.</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="179"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="4.30"/>
                    <measurement group_id="O2" value="-3.3" spread="3.53"/>
                    <measurement group_id="O3" value="-3.3" spread="3.28"/>
                    <measurement group_id="O4" value="-2.6" spread="2.96"/>
                    <measurement group_id="O5" value="-2.7" spread="2.89"/>
                    <measurement group_id="O6" value="-1.5" spread="2.95"/>
                    <measurement group_id="O7" value="-2.7" spread="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Pain Interference With Sleep (11-point Likert Scale)</title>
        <description>Change from Baseline in average pain interference with sleep (11-point Likert scale) where 0=no interference with sleep and 10=worst possible interference with sleep.</description>
        <time_frame>Baseline to end of entire treatment phase visit</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Pain Interference With Sleep (11-point Likert Scale)</title>
          <description>Change from Baseline in average pain interference with sleep (11-point Likert scale) where 0=no interference with sleep and 10=worst possible interference with sleep.</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="203"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="53"/>
                <count group_id="O7" value="441"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.62" spread="2.950"/>
                    <measurement group_id="O2" value="-3.86" spread="2.050"/>
                    <measurement group_id="O3" value="-3.32" spread="2.077"/>
                    <measurement group_id="O4" value="-3.15" spread="2.150"/>
                    <measurement group_id="O5" value="-3.34" spread="1.852"/>
                    <measurement group_id="O6" value="-2.85" spread="2.427"/>
                    <measurement group_id="O7" value="-3.29" spread="2.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Pain Interference With Activity (11-point Likert Scale)</title>
        <description>Change from Baseline in average pain interference with activity (11-point Likert scale) where 0=no interfence with activity and 10=worst possible interference with activity.</description>
        <time_frame>Baseline to end of entire treatment phase visit</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Pain Interference With Activity (11-point Likert Scale)</title>
          <description>Change from Baseline in average pain interference with activity (11-point Likert scale) where 0=no interfence with activity and 10=worst possible interference with activity.</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="203"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="53"/>
                <count group_id="O7" value="441"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.82" spread="2.927"/>
                    <measurement group_id="O2" value="-3.82" spread="2.185"/>
                    <measurement group_id="O3" value="-3.36" spread="2.163"/>
                    <measurement group_id="O4" value="-3.00" spread="2.038"/>
                    <measurement group_id="O5" value="-3.30" spread="1.808"/>
                    <measurement group_id="O6" value="-2.54" spread="2.261"/>
                    <measurement group_id="O7" value="-3.18" spread="2.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life Using the SF-36 Health Survey - Physical Component Summary (PCS)</title>
        <description>Change from Baseline in quality of life using the SF-36 Health Survey - Physical Component Summary (PCS). Values range from 0 to 100 with high values indicating a good condition. Positive change in baseline values indicate improvement in quality of life.</description>
        <time_frame>Baseline to Termination Visit</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life Using the SF-36 Health Survey - Physical Component Summary (PCS)</title>
          <description>Change from Baseline in quality of life using the SF-36 Health Survey - Physical Component Summary (PCS). Values range from 0 to 100 with high values indicating a good condition. Positive change in baseline values indicate improvement in quality of life.</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="179"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="11.25"/>
                    <measurement group_id="O2" value="5.5" spread="10.50"/>
                    <measurement group_id="O3" value="5.1" spread="9.14"/>
                    <measurement group_id="O4" value="3.7" spread="8.80"/>
                    <measurement group_id="O5" value="3.5" spread="6.70"/>
                    <measurement group_id="O6" value="2.1" spread="8.56"/>
                    <measurement group_id="O7" value="4.0" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life Using the SF-36 Health Survey  Mental Component Summary (MCS)</title>
        <description>Change from Baseline in quality of life using the SF-36 Health Survey  Mental Component Summary (MCS). Values range from 0 to 100 with high values indicating a good condition. Positive change in baseline values indicate improvement in quality of life.</description>
        <time_frame>Baseline to Termination Visit</time_frame>
        <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
        <group_list>
          <group group_id="O1">
            <title>Lacosamide 100mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>Lacosamide 200mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O3">
            <title>Lacosamide 300mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O4">
            <title>Lacosamide 400mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O5">
            <title>Lacosamide 500mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O6">
            <title>Lacosamide 600mg/Day</title>
            <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
          </group>
          <group group_id="O7">
            <title>Total</title>
            <description>All modal dose groups combined</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life Using the SF-36 Health Survey  Mental Component Summary (MCS)</title>
          <description>Change from Baseline in quality of life using the SF-36 Health Survey  Mental Component Summary (MCS). Values range from 0 to 100 with high values indicating a good condition. Positive change in baseline values indicate improvement in quality of life.</description>
          <population>Safety population are subjects who took at least one dose of lacosamide (LCM).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="179"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="10.66"/>
                    <measurement group_id="O2" value="-0.1" spread="12.60"/>
                    <measurement group_id="O3" value="0.7" spread="10.78"/>
                    <measurement group_id="O4" value="-1.1" spread="11.09"/>
                    <measurement group_id="O5" value="-3.7" spread="14.34"/>
                    <measurement group_id="O6" value="-0.4" spread="12.02"/>
                    <measurement group_id="O7" value="-0.9" spread="11.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years, 10 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lacosamide 100mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="E2">
          <title>Lacosamide 200mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="E3">
          <title>Lacosamide 300mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="E4">
          <title>Lacosamide 400mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="E5">
          <title>Lacosamide 500mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="E6">
          <title>Lacosamide 600mg/Day</title>
          <description>Modal dose = Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day</description>
        </group>
        <group group_id="E7">
          <title>Total</title>
          <description>All modal dose groups combined</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="205"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="100" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Artioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal angiodysplasia haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="9" subjects_affected="8" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis C antibody positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Electrocardiogram PR prolongation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease mixed cellularity stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Inflammatory carcinoma of the breast</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Shoulder operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Aortic dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="183" subjects_at_risk="205"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="379" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="18" subjects_affected="18" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="21" subjects_affected="17" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="18" subjects_affected="17" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="7" subjects_affected="5" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="57"/>
                <counts group_id="E3" events="21" subjects_affected="13" subjects_at_risk="85"/>
                <counts group_id="E4" events="37" subjects_affected="33" subjects_at_risk="205"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" events="80" subjects_affected="65" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E4" events="25" subjects_affected="19" subjects_at_risk="205"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="46" subjects_affected="37" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E4" events="14" subjects_affected="12" subjects_at_risk="205"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E6" events="6" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="33" subjects_affected="26" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="19" subjects_affected="17" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="205"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="15" subjects_affected="14" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="11" subjects_affected="11" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="57"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E4" events="24" subjects_affected="21" subjects_at_risk="205"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="54" subjects_affected="44" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E4" events="24" subjects_affected="22" subjects_at_risk="205"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="47" subjects_affected="42" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E7" events="22" subjects_affected="19" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="13" subjects_affected="13" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="57"/>
                <counts group_id="E3" events="18" subjects_affected="14" subjects_at_risk="85"/>
                <counts group_id="E4" events="50" subjects_affected="28" subjects_at_risk="205"/>
                <counts group_id="E5" events="11" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E6" events="13" subjects_affected="12" subjects_at_risk="54"/>
                <counts group_id="E7" events="104" subjects_affected="73" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" events="33" subjects_affected="25" subjects_at_risk="205"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="6" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="52" subjects_affected="38" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E4" events="26" subjects_affected="19" subjects_at_risk="205"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="47" subjects_affected="33" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E4" events="19" subjects_affected="12" subjects_at_risk="205"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="44" subjects_affected="30" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E4" events="14" subjects_affected="10" subjects_at_risk="205"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="31" subjects_affected="26" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="21" subjects_affected="15" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="30" subjects_affected="24" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="10" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="14" subjects_affected="10" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="12" subjects_affected="10" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="9" subjects_affected="6" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" events="31" subjects_affected="28" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="12" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="205"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="32" subjects_affected="24" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="9" subjects_affected="9" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="205"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="26" subjects_affected="21" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="16" subjects_affected="14" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="11" subjects_affected="10" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="17" subjects_affected="15" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="11" subjects_affected="10" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E4" events="29" subjects_affected="25" subjects_at_risk="205"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="49" subjects_affected="40" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E4" events="26" subjects_affected="19" subjects_at_risk="205"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E7" events="46" subjects_affected="36" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E4" events="29" subjects_affected="19" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="46" subjects_affected="32" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="28" subjects_affected="23" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="17" subjects_affected="16" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="11" subjects_affected="10" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="57"/>
                <counts group_id="E3" events="31" subjects_affected="23" subjects_at_risk="85"/>
                <counts group_id="E4" events="59" subjects_affected="47" subjects_at_risk="205"/>
                <counts group_id="E5" events="13" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E7" events="127" subjects_affected="99" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="57"/>
                <counts group_id="E3" events="15" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E4" events="37" subjects_affected="31" subjects_at_risk="205"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="70" subjects_affected="56" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E4" events="30" subjects_affected="21" subjects_at_risk="205"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="50" subjects_affected="38" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E4" events="21" subjects_affected="21" subjects_at_risk="205"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E7" events="38" subjects_affected="37" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" events="23" subjects_affected="15" subjects_at_risk="205"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" events="38" subjects_affected="28" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="26" subjects_affected="25" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="205"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="18" subjects_affected="18" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pallanaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="11" subjects_affected="8" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="21" subjects_affected="16" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="13" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="19" subjects_affected="16" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hyporeflexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="17" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="27" subjects_affected="14" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="12" subjects_affected="11" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="205"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="25" subjects_affected="25" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" events="15" subjects_affected="13" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="21" subjects_affected="19" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="12" subjects_affected="9" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="205"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" events="31" subjects_affected="27" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="205"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="25" subjects_affected="19" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="20" subjects_affected="18" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="15" subjects_affected="11" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Wound treatment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Peripheral nerve transposition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="205"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="26" subjects_affected="21" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>UCB has &gt; 60 days but &lt;= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB Clinical Trial Call Center</name_or_title>
      <organization>UCB Pharma</organization>
      <phone>+1 877 822 9493</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

